Novavax, Inc. (NVAX) is a biotechnology company specializing in vaccine development for infectious diseases, with a core business that aligns with Shariah principles by promoting public health. However, financial screening reveals challenges, particularly a high liquidity ratio exceeding thresholds across major standards, leading to non-compliance in index inclusions. The company's permissible activities and low non-permissible income are positive, but purification is required for minor interest income. Overall, while business activities are compliant, financial metrics result in a non-compliant status per index methodologies. Investors should monitor debt and cash management improvements for potential future compliance.